



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/Cancer Care Nova Scotia**

Guidelines for the Role of Rituximab in Chronic Lymphocytic Leukemia (CLL)

Rituximab (R): In **combination** with fludarabine and cyclophosphamide (FC) in **previously untreated** symptomatic patients with documented evidence of CD20-positive chronic lymphocytic leukemia (CLL) (including small lymphocytic leukemia (SLL)) with an ECOG performance status of 0-2, and choose to receive combination chemotherapy. FCR would be a reasonable option for CLL patients (including SLL) **previously treated** with chemotherapy but **not exposed** to a rituximab based regimen. **Retreatment** with FCR could be considered in those CLL patients (including SLL) with relapsed disease who have achieved a response of at least two year's duration from the last FCR administration or beyond.

- This policy recommendation represents a **new guideline document** and a restriction of FCR in previously untreated, previously treated or as retreatment in patients with symptomatic CLL.

(Note: please refer to Record of Recommendation for funding decisions)